Navigation Links
Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
Date:8/5/2011

LAS VEGAS, Aug. 5, 2011 /PRNewswire/ -- Jury selection in the second trial in the largest hepatitis C outbreak in U.S. history has begun in Clark County, Nevada. The Nevada Supreme Court lifted the stay allowing the case to go to trial when it was determined by the court that nurse David Hambrick, a witness for the defense Teva Inc. and Baxter Inc., "does not possess the requisite skill, knowledge or experience to testify as an expert witness regarding the medical cause of hepatitis C transmission at the Endoscopy Clinic of Southern Nevada," and that the defendants must have qualified, competent expert testimony given to a reasonable degree of medical probability for their alternative causation theory. 

(Photo:  http://photos.prnewswire.com/prnh/20110805/LA48404)

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs.  

"There are two primary issues in the Arnold case: the multi-dosing of Propofol between patients from 50mL jumbo infusion vials not intended for short medical procedures like colonoscopies, and the labels on the vials of Propofol provided inadequate warnings about intended use. Teva and Baxter were responsible for providing 50mL infusion vials of Propofol to the Endoscopy centers because profit dictated the decision to do so. Teva and Baxter's attempt to place the blame exclusively on the health care professionals is a complete disregard for the lives of thousands of Nevadans and their families. Drug companies are not allowed to put profit over patient safety," says Robert Eglet.  


'/>"/>
SOURCE Mainor Eglet Law Firm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Sky One Medical Announces Conference Call to Discuss Second Quarter 2011 Results
2. China Nepstar Chain Drugstore to Report Second Quarter 2011 Financial Results on August 23
3. QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
7. Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Isis Reports Financial Results and Highlights for Second Quarter 2011
9. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
10. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
11. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: ... integrated commercial company that provides clinically useful molecular ... it has entered into agreements to successfully restructure ... ("RedPath") and concurrently terminate its royalty and milestone ... debt to RedPath amounting to $9.34 million is ...
(Date:3/23/2017)... March 23, 2017 CENTRO DE IMAGEM DIAGNOSTICOS ... paragraph 4 of Law 6,404/76 and Instruction 358/02 of ... its shareholders and the market in general that it ... Centro de Diagnosticos por Imagem Ltda. (" CDI "), ... in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " and " ...
(Date:3/23/2017)... 23, 2017  The goal of the pilot ... and track prescription drugs as they are distributed in ... to requirements from US FDA to better protect consumers ... medicines. Blockchain startup Chronicled, which links ... and blockchain technology and recently raised $6.25M, and the ...
Breaking Medicine Technology:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital ... President and Director, AMN Healthcare: Susan Salka , 43rd President of the United ... The Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... non-steroidal skincare products, was awarded as winners of American Dreams & Good Housekeeping ... was hosted jointly by HSN and Good Housekeeping. , Steven Wang, MD ...
(Date:3/23/2017)... Washington, DC (PRWEB) , ... March 23, 2017 , ... ... for Dental Choice has helped score a major victory in Europe for public health ... lead. , Based on rigorous scientific research and the overwhelming support of ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A ... God. “A Respectful Response To Atheist Manifesto” is the creation of published author ... wife, Nancy, for sixty years. He holds graduate degrees from Kent State University ...
Breaking Medicine News(10 mins):